William CPA - Organogenesis Holdings Secretary
| ORGO Stock | USD 2.79 0.05 1.82% |
Executive
William CPA is Secretary of Organogenesis Holdings
| Address | 85 Dan Road, Canton, MA, United States, 02021 |
| Phone | 781 575 0775 |
| Web | https://organogenesis.com |
Organogenesis Holdings Management Efficiency
The company has return on total asset (ROA) of 0.0201 % which means that it generated a profit of $0.0201 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0215 %, meaning that it created $0.0215 on every $100 dollars invested by stockholders. Organogenesis Holdings' management efficiency ratios could be used to measure how well Organogenesis Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of May 2024, Return On Tangible Assets is likely to grow to 0.01. Also, Return On Capital Employed is likely to grow to 0.05. At this time, Organogenesis Holdings' Return On Assets are very stable compared to the past year. As of the 20th of May 2024, Asset Turnover is likely to grow to 1.20, while Total Assets are likely to drop about 292.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tracie Haas | AbbVie Inc | N/A | |
| Winselow Tucker | Eli Lilly and | 56 | |
| Duane Arsdale | Johnson Johnson | N/A | |
| Chirfi Guindo | Merck Company | 58 | |
| Peter Dannenbaum | Merck Company | N/A | |
| Tom Cavanaugh | Johnson Johnson | N/A | |
| Celine Martin | Johnson Johnson | N/A | |
| Susan Esq | Biogen Inc | 67 | |
| Kimberly Jablonski | Bristol Myers Squibb | N/A | |
| Jacquie CFA | Gilead Sciences | N/A | |
| Jim Greffet | Eli Lilly and | N/A | |
| Elizabeth Forminard | Johnson Johnson | 53 | |
| David MD | Eli Lilly and | N/A | |
| Elizabeth Shea | AbbVie Inc | N/A | |
| Linda Higgins | Gilead Sciences | 62 | |
| Francesca DeMartino | Pfizer Inc | N/A | |
| Charles Triano | Biogen Inc | N/A | |
| Dalton III | Merck Company | 57 | |
| Michael Bodner | Johnson Johnson | N/A | |
| Eric Dozier | Eli Lilly and | 56 | |
| Guy MD | Johnson Johnson | N/A | |
Management Performance
| Return On Equity | 0.0215 | ||||
| Return On Asset | 0.0201 |
Organogenesis Holdings Leadership Team
Elected by the shareholders, the Organogenesis Holdings' board of directors comprises two types of representatives: Organogenesis Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Organogenesis. The board's role is to monitor Organogenesis Holdings' management team and ensure that shareholders' interests are well served. Organogenesis Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Organogenesis Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Sr, CEO, President | ||
| BA Esq, VP Counsel | ||
| Patrick Bilbo, Chief Officer | ||
| Thomas Pearl, Vice Resources | ||
| Zorina Pitkin, VP Systems | ||
| Brian Grow, Chief Officer | ||
| Kurt Matheson, VP Marketing | ||
| David Francisco, Chief Officer | ||
| William CPA, Secretary |
Organogenesis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Organogenesis Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0215 | ||||
| Return On Asset | 0.0201 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 393.29 M | ||||
| Shares Outstanding | 132.57 M | ||||
| Shares Owned By Insiders | 32.87 % | ||||
| Shares Owned By Institutions | 43.71 % | ||||
| Number Of Shares Shorted | 9.74 M | ||||
| Price To Earning | 17.12 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.Note that the Organogenesis Holdings information on this page should be used as a complementary analysis to other Organogenesis Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Organogenesis Stock analysis
When running Organogenesis Holdings' price analysis, check to measure Organogenesis Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Organogenesis Holdings is operating at the current time. Most of Organogenesis Holdings' value examination focuses on studying past and present price action to predict the probability of Organogenesis Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Organogenesis Holdings' price. Additionally, you may evaluate how the addition of Organogenesis Holdings to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Organogenesis Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 11.307 | Earnings Share 0.04 | Revenue Per Share 3.313 | Quarterly Revenue Growth 0.022 | Return On Assets 0.0201 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.